drugset
drugset / Trial / NCT05565950

AI-09 In Subjects With Glabellar Lines, GL-101

NCT05565950 ↗

Phase 1/2 Completed 72 enrolled Eirion Therapeutics Inc.
RandomizedSequentialDouble-blindTreatment

Summary

AI-09 In Subjects with Glabellar Lines

Timeline

Start
2022-09-03
Primary completion
2024-06-03
Completion
2024-06-03

Drugs

EvaluationDrugModalityDoseRoute
Subject AI-09 Protein / enzyme biologic — Intramuscular

Indications

No indication recorded.